drugset / Trial / NCT02576938
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.
Timeline
- Start
- 2016-02
- Primary completion
- 2017-02
- Completion
- 2017-03
Outcome
Met primary endpoint
release “Results presented at EADV show baricitinib significantly improved clinical and patient-reported outcomes compared to placebo in moderate-to-severe atopic dermatitis patients” incyte.com ↗
Publications
- Katoh N, Takita Y, Isaka Y, Nishikawa A, Torisu-Itakura H, Saeki H. Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials. Dermatol Ther (Heidelb). 2022 Dec;12(12):2765-2779. doi: 10.1007/s13555-022-00828-5. Epub 2022 Oct 18.
- King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes FP, Simpson EL. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. Am J Clin Dermatol. 2021 May;22(3):395-405. doi: 10.1007/s40257-021-00602-x. Epub 2021 Apr 7.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | — | Oral |
| Background | Triamcinolone | Other / unclassified | 0.1 % | Topical |